Nothing in the discussion above constitutes medical advice, describes a treatment for any individual, or makes cosmetic or therapeutic claims about effects in people who purchase the compound for research
Notably, the STEP (Semaglutide Treatment Effect in People with obesity) trials, which specifically examined body composition, demonstrated substantial weight loss compared with placebo (NCT03548935) [53], and reductions in fat mass and visceral adipose tissue were accompanied by decreases in lean mass, although the proportion of lean mass relative to total body mass increased (NCT04074161) [54]
Their marketing references 503A and 503B certified pharmacy partners, but the FDAs April 2026 clarification means compounded semaglutide can only legally come from 503A pharmacies right now
They must source ingredients from FDA-registered manufacturers
As a result, riboflavin concentrations were expressed per gram of creatinine